# Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

> **NCT00007865** · PHASE2 · COMPLETED · sponsor: **University of Nebraska**

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** carboplatin
- **DRUG:** etoposide
- **DRUG:** ifosfamide

## Key facts

- **NCT ID:** NCT00007865
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09-01
- **Primary completion:** 2004-03-01
- **Final completion:** 2008-04-22
- **Target enrollment:** — (—)
- **Last updated:** 2023-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00007865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00007865, "Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00007865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*